Xenon Pharmaceuticals Ownership | Who Owns Xenon Pharmaceuticals?


OverviewForecastFinancialsChartTranscripts

Xenon Pharmaceuticals Ownership Summary


Xenon Pharmaceuticals is owned by 115.97% institutional investors, 0.11% insiders. Fmr is the largest institutional shareholder, holding 11.05% of XENE shares. Vanguard Health Care Inv is the top mutual fund, with 3.33% of its assets in Xenon Pharmaceuticals shares.

XENE Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockXenon Pharmaceuticals115.97%0.11%-16.08%
SectorHealthcare Stocks 244.37%12.11%-156.48%
IndustryBiotech Stocks 379.01%11.75%-290.76%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Fmr9.65M11.05%$582.35M
Blackrock funding, inc. /de7.52M8.61%$454.06M
Avoro capital advisors5.78M6.61%$348.75M
Janus henderson group4.18M5.27%$242.86M
Polar capital4.57M5.23%$275.88M
Driehaus capital management4.42M5.06%$266.70M
Price t rowe associates inc /md/3.25M3.72%$196.06M
Jpmorgan chase2.62M3.00%$157.38M
Capital investors2.36M2.70%$142.55M
Blackrock2.10M2.70%$81.72M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Tls advisors30.96K5.49%$1.87M
Saturn v capital management503.70K4.44%$20.22M
Affinity asset advisors1.59M4.35%$96.27M
First turn management600.20K3.88%$36.23M
Tri locum partners lp366.10K3.38%$14.70M
Foresite capital management iv160.00K3.33%$9.66M
Great point partners200.00K3.31%$8.03M
Altium capital management lp288.00K3.20%$11.29M
Avoro capital advisors5.78M3.13%$348.75M
Dafna capital management250.77K2.89%$15.14M

Top Buyers

HolderShares% AssetsChange
Price t rowe associates inc /md/3.25M0.02%1.92M
Blackrock funding, inc. /de7.52M0.01%1.88M
T. rowe price investment management2.17M0.09%1.22M
Two sigma investments, lp1.64M0.07%1.04M
Invesco903.46K0.00%844.36K

Top Sellers

HolderShares% AssetsChange
Wellington management group llp1.43M0.01%-3.40M
Paradigm biocapital advisors lp---2.04M
Holocene advisors, lp---1.52M
Citadel advisors1.40M0.01%-1.25M
Fmr9.65M0.03%-1.17M

New Positions

HolderShares% AssetsChangeValue
Panagora asset management664.03K0.12%664.03K$40.08M
Tri locum partners lp366.10K3.38%366.10K$14.70M
Sixth street partners management company249.47K0.00%249.47K$15.06M
Axa investment managers176.16K0.02%176.16K$7.07M
Point72 asset management130.38K0.01%130.38K$7.87M

Sold Out

HolderChange
Dinuzzo private wealth-2.00
Tortoise investment management-2.00
Td private client wealth-3.00
American national bank-5.00
Hexagon capital partners-6.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20263235.56%101,294,1791.07%1150.73%180-12.20%8636.51%
Mar 31, 2026110-57.85%10,120,863-88.02%120.11%74-45.59%20-73.33%
Dec 31, 2025150-34.78%31,012,004-63.22%390.34%73-31.13%49-30.00%
Sep 30, 2025142-30.39%50,518,761-37.12%630.61%62-45.13%48-12.73%
Jun 30, 20252110.48%83,114,83911.81%1051.18%11626.09%57-18.57%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Health Care Inv3.21M3.33%-127.83K
American Funds SMALLCAP World A3.12M3.23%-377.13K
iShares Russell 2000 ETF2.48M2.56%-44.06K
Polar Capital Biotech S Inc2.45M2.53%-
Strategic Advisers Fidelity US TtlStk2.01M2.08%74.10K
Polar Capital Healthcare Opports Inc1.69M1.75%150.00K
Fidelity Select Health Care1.08M1.12%-70.00K
JPM US Mid Cap Growth-Composite962.10K1.00%536.10K
JPMorgan Mid Cap Growth I962.10K0.99%543.50K
T. Rowe Price New Horizons902.59K0.93%452.00K

Recent Insider Transactions


DateNameRoleActivityValue
Aug 28, 2026KENNEY CHRISTOPHER JOHN Chief Medical OfficerSell$42.68K
Aug 28, 2026KENNEY CHRISTOPHER JOHN Chief Medical OfficerSell$383.15K
Aug 11, 2026GANNON STEVEN-Sell$640.55K
Jun 05, 2026PATOU GARY-Sell$70.25K
Jun 05, 2026Cannon Gillian-Sell$63.24K

Insider Transactions Trends


DateBuySell
2026 Q3-3
2026 Q2-2
2026 Q1-17
2025 Q4-5
2025 Q2-1

XENE Ownership FAQ


Who Owns Xenon Pharmaceuticals?

Xenon Pharmaceuticals shareholders are primarily institutional investors at 115.97%, followed by 0.11% insiders and -16.08% retail investors. The average institutional ownership in Xenon Pharmaceuticals's industry, Biotech Stocks , is 379.01%, which Xenon Pharmaceuticals falls below.

Who owns the most shares of Xenon Pharmaceuticals?

Xenon Pharmaceuticals’s largest shareholders are Fmr (9.65M shares, 11.05%), Blackrock funding, inc. /de (7.52M shares, 8.61%), and Avoro capital advisors (5.78M shares, 6.61%). Together, they hold 26.27% of Xenon Pharmaceuticals’s total shares outstanding.

Does Blackrock own Xenon Pharmaceuticals?

Yes, BlackRock owns 2.70% of Xenon Pharmaceuticals, totaling 2.1M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 81.72M$. In the last quarter, BlackRock decreased its holdings by -26.034K shares, a -1.23% change.

Who is Xenon Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Tls advisors is Xenon Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 5.49% of its assets in 30.96K Xenon Pharmaceuticals shares, valued at 1.87M$.

Who is the top mutual fund holder of Xenon Pharmaceuticals shares?

Vanguard Health Care Inv is the top mutual fund holder of Xenon Pharmaceuticals shares, with 3.33% of its total shares outstanding invested in 3.21M Xenon Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools